SCHEMBL7737831

SCHEMBL7737831

CCCCn1ccc(-c2ccc(OC)cc2)c(C(=O)OCC)c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.51
▸ HTT P42858 5/20 0.51
▸ GAA P10253 3/20 0.51
▸ KDM4E B2RXH2 3/20 0.51
▸ POLB P06746 2/20 0.51
▸ GRM2 Q14416 5/20 0.46
▸ GRM6 O15303 1/20 0.45
▸ MAPT P10636 4/20 0.44
▸ LMNA P02545 3/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ HSP90AA1 P07900 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ MPI P34949 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ HKDC1 Q2TB90 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7735825 0.87 GFER (0.48) ALDH1A1HTTGAAKDM4EPOLB
SCHEMBL7737830 0.87 GRM2 (0.49) ALDH1A1HTTGAAKDM4EPOLB
SCHEMBL7735824 0.74 GRM2 (0.49) KDM4EGRM2LMNAKMT2AMAPK1
SCHEMBL7736088 0.72 PTGER4 (0.44) GRM2MEN1KMT2AL3MBTL1
SCHEMBL7725865 0.72 MAPT (0.44) ALDH1A1HTTGRM2MAPTLMNA
SCHEMBL2188130 0.70 GRM2 (0.46) GRM2MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL16057331 0.68 DCTPP1 (0.43) ALDH1A1HTTGAAKDM4EPOLB
SCHEMBL7737859 0.68 MEN1 (0.45) ALDH1A1KDM4EGRM2MEN1KMT2A
SCHEMBL7734365 0.68 ICMT (0.45) ALDH1A1KDM4EGRM2MAPTLMNA
SCHEMBL2186301 0.67 GRM2 (0.47) KDM4EGRM2MEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452008-B2 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-17 — — US disclosed
US-20010051732-A1 Pyridone derivatives and process for preparing the same SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2001-12-13 — — US disclosed
US-6300500-B1 Preparation of pyridone derivatives using phthalimido containing starting material SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-10-09 — — US disclosed
EP-1086948-A1 PYRIDONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-03-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051732-A1 Pyridone derivatives and process for preparing the same HK1, HPD, ALK ALDH1A1 716/4885HTT 369/4885GAA 4437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback